NO960049L - Fremstilling og stabilisering av celler - Google Patents

Fremstilling og stabilisering av celler

Info

Publication number
NO960049L
NO960049L NO960049A NO960049A NO960049L NO 960049 L NO960049 L NO 960049L NO 960049 A NO960049 A NO 960049A NO 960049 A NO960049 A NO 960049A NO 960049 L NO960049 L NO 960049L
Authority
NO
Norway
Prior art keywords
blood
leucocytes
composition
stabilizing
novel
Prior art date
Application number
NO960049A
Other languages
English (en)
Norwegian (no)
Other versions
NO960049D0 (no
Inventor
Vivian Granger
David Barnett
John Tennison Reilly
Petra Susanne Maria Mayr
Shawn Patrick Fay
Original Assignee
North Gen Hospital Nhs Trust
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939313962A external-priority patent/GB9313962D0/en
Priority claimed from GB9406698A external-priority patent/GB9406698D0/en
Application filed by North Gen Hospital Nhs Trust filed Critical North Gen Hospital Nhs Trust
Publication of NO960049D0 publication Critical patent/NO960049D0/no
Publication of NO960049L publication Critical patent/NO960049L/no

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5002Partitioning blood components
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • G01N33/56972White blood cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • G01N33/56977HLA or MHC typing
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/96Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2496/00Reference solutions for assays of biological material
    • G01N2496/05Reference solutions for assays of biological material containing blood cells or plasma
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/10Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/101666Particle count or volume standard or control [e.g., platelet count standards, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Ecology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO960049A 1993-07-05 1996-01-05 Fremstilling og stabilisering av celler NO960049L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB939313962A GB9313962D0 (en) 1993-07-05 1993-07-05 Preparation and stabilisation of leucocytes
GB939315871A GB9315871D0 (en) 1993-07-05 1993-07-20 Preparation and stabilisation of leucocytes
GB9406698A GB9406698D0 (en) 1994-04-05 1994-04-05 Preparation and stabilisation of cell suspensions
PCT/EP1994/002189 WO1995001796A1 (fr) 1993-07-05 1994-07-05 Preparation et stabilisation de cellules

Publications (2)

Publication Number Publication Date
NO960049D0 NO960049D0 (no) 1996-01-05
NO960049L true NO960049L (no) 1996-03-05

Family

ID=27266764

Family Applications (1)

Application Number Title Priority Date Filing Date
NO960049A NO960049L (no) 1993-07-05 1996-01-05 Fremstilling og stabilisering av celler

Country Status (14)

Country Link
US (2) US6197540B1 (fr)
EP (1) EP0708649B1 (fr)
JP (1) JPH09503051A (fr)
AT (1) ATE241368T1 (fr)
AU (2) AU700699B2 (fr)
BR (1) BR9407003A (fr)
CA (1) CA2166729A1 (fr)
DE (2) DE708649T1 (fr)
ES (1) ES2197168T3 (fr)
FI (1) FI960045A0 (fr)
GB (1) GB2279653B (fr)
NO (1) NO960049L (fr)
NZ (1) NZ271318A (fr)
WO (1) WO1995001796A1 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09503051A (ja) * 1993-07-05 1997-03-25 ノーザン ジェネラル ホスピタル エヌ.エイチ.エス.トラスト 細胞の調製および安定化
JPH10503008A (ja) * 1994-04-05 1998-03-17 ノーザン ジェネラル ホスピタル エヌ.エイチ.エス.トラスト 細胞懸濁液の安定化および調製
GB2313288B (en) 1996-05-24 2000-07-12 North Gen Hospital Nhs Trust Specimen collection fluid
EP1182457A1 (fr) * 2000-08-17 2002-02-27 Mallinckrodt Baker B.V. Méthode et réactif pour l'analyse des échantillons sanguins, en particulier pour les applications vétérinaires
US6913932B2 (en) * 2002-08-23 2005-07-05 Beckman Coulter, Inc. Formaldehyde-ammonium salt complexes for the stabilization of blood cells
DK1816461T3 (da) * 2002-10-16 2020-04-14 Streck Laboratories Inc Fremgangsmåde og indretning til indsamling og sikring af celler til brug for analyse
US7267980B1 (en) 2003-04-04 2007-09-11 Research & Diagnostic Systems, Inc. Stabilizing solution for cells and tissues
US20050085028A1 (en) * 2003-10-21 2005-04-21 International Business Machines Corporation Method and structure to suppress external latch-up
CN100376669C (zh) * 2005-02-25 2008-03-26 深圳迈瑞生物医疗电子股份有限公司 生物红细胞体积长期稳定的处理方法
US20070015134A1 (en) * 2005-07-15 2007-01-18 Beckman Coulter, Inc. Quantitative stabilized cell reference control products and methods
US9424392B2 (en) 2005-11-26 2016-08-23 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
CA2730191C (fr) * 2008-07-11 2018-06-19 Health Protection Agency Standards cellulaires stimules
US20100167271A1 (en) * 2008-12-30 2010-07-01 Streck, Inc. Method for screening blood using a preservative that may be in a substantially solid state form
US11634747B2 (en) * 2009-01-21 2023-04-25 Streck Llc Preservation of fetal nucleic acids in maternal plasma
US8304187B2 (en) 2009-02-18 2012-11-06 Streck, Inc. Preservation of cell-free RNA in blood samples
EP2499259B1 (fr) * 2009-11-09 2016-04-06 Streck Inc. Stabilisation d'arn et extraction d'arn présent dans des cellules intactes d'un échantillon sanguin
US11339429B2 (en) 2010-05-18 2022-05-24 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US11326208B2 (en) 2010-05-18 2022-05-10 Natera, Inc. Methods for nested PCR amplification of cell-free DNA
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
CA3037126C (fr) 2010-05-18 2023-09-12 Natera, Inc. Procedes de classification de ploidie prenatale non invasive
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US11332793B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for simultaneous amplification of target loci
US11332785B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11408031B2 (en) 2010-05-18 2022-08-09 Natera, Inc. Methods for non-invasive prenatal paternity testing
JP6153874B2 (ja) 2011-02-09 2017-06-28 ナテラ, インコーポレイテッド 非侵襲的出生前倍数性呼び出しのための方法
US9956281B2 (en) 2011-05-04 2018-05-01 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
CA2917912C (fr) 2013-07-24 2019-09-17 Streck, Inc. Compositions et methodes de stabilisation de cellules tumorales circulantes
EP3134541B1 (fr) 2014-04-21 2020-08-19 Natera, Inc. Détection des ploïdies dans des segments chromosomiques en cancer
US11168351B2 (en) 2015-03-05 2021-11-09 Streck, Inc. Stabilization of nucleic acids in urine
WO2016183106A1 (fr) 2015-05-11 2016-11-17 Natera, Inc. Procédés et compositions pour la détermination de la ploïdie
US20170145475A1 (en) 2015-11-20 2017-05-25 Streck, Inc. Single spin process for blood plasma separation and plasma composition including preservative
WO2018022991A1 (fr) 2016-07-29 2018-02-01 Streck, Inc. Composition de suspension pour contrôle d'analyse hématologique
WO2018067517A1 (fr) 2016-10-04 2018-04-12 Natera, Inc. Procédés pour caractériser une variation de nombre de copies à l'aide d'un séquençage de ligature de proximité
US10011870B2 (en) 2016-12-07 2018-07-03 Natera, Inc. Compositions and methods for identifying nucleic acid molecules
US11882823B2 (en) 2017-01-22 2024-01-30 Chryos, Llc Composition and method of use of the same for preserving cells for analysis
US12024738B2 (en) 2018-04-14 2024-07-02 Natera, Inc. Methods for cancer detection and monitoring
WO2019210306A1 (fr) * 2018-04-27 2019-10-31 Momenta Pharmaceuticals , Inc. Préparation de sang
US11525159B2 (en) 2018-07-03 2022-12-13 Natera, Inc. Methods for detection of donor-derived cell-free DNA
CN113325171B (zh) * 2021-08-02 2021-12-21 天津康博尔生物基因技术有限公司 检测人体红细胞叶酸含量的试剂盒、检测方法及用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1068862B (de) 1957-05-03 1959-11-12 Penicillin-Gesellschaft Dauelsberg a Co., Göttingen Verfahren zur Verlängerung der Haltbarkeit von Blutkonserven
DE1147004B (de) * 1959-10-16 1963-04-11 Dr Med Herbert Fischer Verfahren zur Konservierung von lebenden menschlichen oder tierischen Zellpraeparaten, insbesondere von Blut und Blutbestandteilen
CA933092A (en) * 1969-04-10 1973-09-04 V. Collins Zeola Method of prolonging the viability of lymphocytes
FR2202688B1 (fr) 1972-10-17 1977-04-15 Cepbepe
US4045488A (en) 1974-11-06 1977-08-30 Pfizer Inc. Aminophenyltetralin compounds
IT1065125B (it) 1975-08-20 1985-02-25 Boehringer Mannheim Gmbh Processo per mantenere costante l attivita di fosfatasi alcalina e siero di controllo contenente tale fosfatasi
DE2551208C3 (de) * 1975-11-14 1981-05-27 Behringwerke Ag, 3550 Marburg Verfahren zur Herstellung einer stabilen Erythrozyten-Präparation
US4040785A (en) 1976-10-18 1977-08-09 Technicon Instruments Corporation Lysable blood preservative composition
US4152208A (en) * 1977-03-29 1979-05-01 Hoffmann-La Roche Inc. Stabilized leucocytes
US4302355A (en) * 1977-08-01 1981-11-24 Warner-Lambert Company Platelet reference control
DE2828820A1 (de) * 1977-08-01 1979-02-08 Warner Lambert Co Verfahren zur herstellung einer stabilen blutplaettchensuspension und nach dem verfahren erhaltene stabile blutplaettchensuspension
US4324687A (en) 1979-02-15 1982-04-13 Louderback Allan Lee Blood biochemistry control standard
DE2949824A1 (de) * 1979-12-12 1981-07-02 Marianne Dr. 5000 Köln Sehrbundt Verfahren zur stabilisierung von lymphozyten/thrombozytennmischsuspensionen
US4346018A (en) 1980-06-16 1982-08-24 Coulter Electronics, Inc. Multi-purpose blood diluent and lysing agent for differential determination of lymphoid-myeloid population of leukocytes
US4405719A (en) 1981-05-29 1983-09-20 Coulter Electronics, Inc. Method of stabilizing platelets for determining multiple platelet parameters in reference control and calibrator compositions; diluents therefor; and combination stabilization procedures
US4704352A (en) 1985-06-25 1987-11-03 Baxter Travenol Laboratories, Inc. L-ascorbate-2-phosphate salts in blood cell storage
DE3663453D1 (en) 1985-08-08 1989-06-29 Eberhard Liss Method for inhilition of the reduction of the glucose-content in blood
US4675185A (en) * 1985-12-06 1987-06-23 Baxter Travenol Laboratories, Inc. Solution for stabilizing red blood cells during storage
US4729959A (en) 1986-02-24 1988-03-08 Streck Laboratories, Inc. Glucose reference control for glucose test strips
US4806343A (en) 1986-03-13 1989-02-21 University Of Southwestern Louisiana Cryogenic protectant for proteins
IT1188132B (it) * 1986-05-07 1987-12-30 Fameccanica Spa Procedimento e dispositivo per la produzione di film perforati particolarmente film perforati di materiale plastico per articoli igienico sanitari
US5250438A (en) 1990-05-09 1993-10-05 Streck Laboratories, Inc. Method for differential determination of white blood cells using diazolidinyl urea to stabilize white blood cells
SU1767436A1 (ru) 1990-05-22 1992-10-07 Черновицкий Государственный Университет Способ определени глюкозы в крови
US5260048A (en) 1991-05-08 1993-11-09 Streck Laboratories, Inc. Tissue fixative solution and method
US5270208A (en) * 1991-05-09 1993-12-14 Streck Laboratories, Inc. White blood cell hematology control
JPH0820452B2 (ja) 1991-12-16 1996-03-04 株式会社いかがく 血液中糖類の微生物による消費阻止方法
US5422277A (en) * 1992-03-27 1995-06-06 Ortho Diagnostic Systems Inc. Cell fixative composition and method of staining cells without destroying the cell surface
WO1993021928A1 (fr) 1992-04-24 1993-11-11 Streck Laboratories, Inc. Solution temoin de glucose liquide et procede de preparation
US5407794A (en) * 1992-09-08 1995-04-18 Cytocolor Inc. Oxazine stained lymphocytes and method
CA2123227C (fr) 1992-09-10 2009-04-28 Wayne L. Ryan Methode et composition de conservation d'antigenes et procede d'utilisation de materiel cytologique produit par cette methode
FR2705359B1 (fr) * 1993-05-19 1995-08-18 Immunotech Sa Méthode de protection des cellules leucocytaires, composition protectrice, composition de sang protégée, et méthode d'analyse sanguine.
JPH09503051A (ja) 1993-07-05 1997-03-25 ノーザン ジェネラル ホスピタル エヌ.エイチ.エス.トラスト 細胞の調製および安定化
JPH10503008A (ja) 1994-04-05 1998-03-17 ノーザン ジェネラル ホスピタル エヌ.エイチ.エス.トラスト 細胞懸濁液の安定化および調製

Also Published As

Publication number Publication date
JPH09503051A (ja) 1997-03-25
US6197539B1 (en) 2001-03-06
AU700699B2 (en) 1999-01-14
WO1995001796A1 (fr) 1995-01-19
US6197540B1 (en) 2001-03-06
CA2166729A1 (fr) 1995-01-19
EP0708649B1 (fr) 2003-05-28
AU4441096A (en) 1996-06-06
AU7490994A (en) 1995-02-06
DE708649T1 (de) 2001-09-20
GB9413558D0 (en) 1994-08-24
NO960049D0 (no) 1996-01-05
ES2197168T3 (es) 2004-01-01
EP0708649A1 (fr) 1996-05-01
ATE241368T1 (de) 2003-06-15
NZ271318A (en) 1998-08-26
DE69432751D1 (de) 2003-07-03
FI960045A (fi) 1996-01-05
BR9407003A (pt) 1996-03-26
FI960045A0 (fi) 1996-01-05
GB2279653B (en) 1998-02-11
DE69432751T2 (de) 2004-04-29
GB2279653A (en) 1995-01-11

Similar Documents

Publication Publication Date Title
NO960049L (no) Fremstilling og stabilisering av celler
AU557006B2 (en) Protein compositions substantially free from infectious agents
CO4820440A1 (es) Composiciones que contienen adenovirus recombinantes concentrados
ES8506190A1 (es) Un metodo para estabilizar un activador de plasminogeno de tejido.
WO1994024984A3 (fr) Compositions anti-inflammatoires contenant de l'acide eicosapentaenoique portant du monogalactosyldiacylglycerol et procedes de preparation
DE3381468D1 (de) Verfahren zur herstellung eines lyophilisierten radiografischen abbildungsbestecks.
WO1991008981A3 (fr) Solutions pour stabiliser des solutions contenant du peroxyde d'hydrogene
EA199900334A1 (ru) Циклопентеноны, способы их получения и применение
ATE17363T1 (de) Verfahren zur herstellung von hochelastischen schaeumen und alkoxysilicium-verbindung(en) als schaumstabilisatoren hierfuer.
ATE287255T1 (de) Stabile flüssigkeiten mit hohem glycerolgehalt, die sulfosuccinsäuremonoester enthalten
JPS5547657A (en) Fluorine contained 1*44dihydropyridine compound and medical use
ATE283044T1 (de) Compactin zur behandlung von entzündungen
EP0124314A3 (fr) 3H-indéno(1,2-c)pyridazine-3-ones
JPS56106594A (en) Stabilizing method of plasminogen
ES8506621A1 (es) Procedimiento de preparar nuevas bencensulfonil-lactamas
DE3885577T2 (de) Luciferase.
EP0351591A3 (fr) 2-Tert.-butyl-4-chloro-5-(4-tert.-butyl-benzylthio)-3(2H)-pyridazinone pour lutter contre les limaces et les escargots
JPS5576814A (en) Preservative solution for organ transplant
JPS6452727A (en) Antiallergic eye drop
ATE103974T1 (de) Verfahren zur stabilisierung des lactoperoxidase- enzyms in produkten.
JPS5714587A (en) Stabilizing method of ascorbic acid
EP0381142A3 (fr) Méthode pour l'utilisation de dérivés d'acides aryl- ou hétéroaryl-1-alkyl-pyrrole-2-carboxyliques dans le traitement de maladies en relation avec l'interleukine-1
YU4797A (sh) Žučne kiseline i njihovi derivati kao hipoglikemična sredstva
JPS5421700A (en) Ion-beam processing method
JPS57105187A (en) Stabilization of liquid pectinase

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application